PMCB at a glance
The past year
Chart+600.1% $5.51, close Nov 16
- From the highest close
- −28.7%
- Vs the 200-day average
- +464.1%
Short interest
History50,675 shares
- Of shares outstanding
- 0.47%
- Since the last report
- −27.7%
- Days to cover
- 1.2 days
- Settled
- Oct 30, 2026
Insider buying, 7 days
FilingsNone filed this week
- Form 4s filed
- Nov 10 – Nov 16
Understand the Business
Why the Stock Moved
Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.
PMCB price history
Loading recent earnings…
Investment thesis
What must happen next
Cell-in-a-Box must move from proprietary technology to externally validated cancer-therapy asset, because PharmaCyte has no observable commercial demand engine today.WeakeningMateriality: High
Profile description identifies PharmaCyte as a biotechnology company focused on cellular therapies for cancer based on proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box. If validation arrives, the company may be worth more than its balance sheet; if not, owners are left funding a pre-revenue option with declining time value.
Watch: Regulators refuse to allow meaningful clinical advancement of Cell-in-a-Box or require studies the company cannot fund.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Profile description identifies PharmaCyte as a biotechnology company focused on cellular therapies for cancer based on proprietary cellulose-based live cell.
Open source ↗Cash runway is the survival mechanism: PharmaCyte can preserve the Cell-in-a-Box option only if cash remains sufficient to fund development without desperate financing.HoldingMateriality: High
Cash and cash equivalents were $18.6 million at FY2026 year-end. A long runway lets shareholders wait for validation; a short runway transfers upside to new capital providers or forces program retrenchment.
Watch: A required clinical or manufacturing program sharply increases spending before any partner funding is secured.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Cash and cash equivalents were $18.6 million at FY2026 year-end.
Open source ↗Operating spending must stay staged to credible milestones, because a pre-revenue biotech cannot create per-share value by increasing burn faster than evidence quality improves.WeakeningMateriality: Medium
FY2026 GAAP operating cash flow was negative $5.2 million. Disciplined spend extends the time available for a breakthrough; uncontrolled spend shortens runway and raises dilution risk before the asset is de-risked.
Watch: Management commits to materially larger development, manufacturing, or corporate spending without a clearly disclosed clinical, regulatory, or strategic milestone.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
FY2026 GAAP operating cash flow was negative $5.2 million.
Open source ↗Investors should treat reported earnings swings as non-core unless tied to product validation, because PharmaCyte’s value driver is balance-sheet-funded development rather than recurring income.StrengtheningMateriality: Medium
GAAP net income was a loss of $19.4 million in FY2026. This prevents overvaluing accounting gains or losses that do not change the probability of Cell-in-a-Box becoming valuable.
Watch: Future reported income is generated by a recurring license, royalty, product sale, or partner payment tied to Cell-in-a-Box.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP net income was a loss of $19.4 million in FY2026.
Open source ↗Liability growth must not crowd out development capital, because the investment case depends on cash reaching Cell-in-a-Box milestones rather than satisfying claims on the balance sheet.WeakeningMateriality: Medium
Total liabilities were $11.8 million at FY2026 year-end. If liabilities absorb cash or senior claims rise, common shareholders get less of any eventual platform upside.
Watch: New debt, preferred securities, litigation obligations, or vendor liabilities take priority over common shareholders before clinical validation.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Total liabilities were $11.8 million at FY2026 year-end.
Open source ↗
Full investment case & evidence
Loading the original research archive…
Original research
Cell-in-a-Box must move from proprietary technology to externally validated cancer-therapy asset, because PharmaCyte has no observable commercial demand engine today. If validation arrives, the company may be worth more than its balance sheet; if not, owners are left funding a pre-revenue option with declining time value.
Cash runway is the survival mechanism: PharmaCyte can preserve the Cell-in-a-Box option only if cash remains sufficient to fund development without desperate financing. A long runway lets shareholders wait for validation; a short runway transfers upside to new capital providers or forces program retrenchment.
Operating spending must stay staged to credible milestones, because a pre-revenue biotech cannot create per-share value by increasing burn faster than evidence quality improves. Disciplined spend extends the time available for a breakthrough; uncontrolled spend shortens runway and raises dilution risk before the asset is de-risked.
Investors should treat reported earnings swings as non-core unless tied to product validation, because PharmaCyte’s value driver is balance-sheet-funded development rather than recurring income. This prevents overvaluing accounting gains or losses that do not change the probability of Cell-in-a-Box becoming valuable.
Liability growth must not crowd out development capital, because the investment case depends on cash reaching Cell-in-a-Box milestones rather than satisfying claims on the balance sheet. If liabilities absorb cash or senior claims rise, common shareholders get less of any eventual platform upside.
All standing thesis claims
Original report summary
PharmaCyte is a cash-funded, pre-revenue biotech option on whether its proprietary Cell-in-a-Box live-cell encapsulation technology can become a clinically validated cancer therapy before the balance sheet is consumed.
Bull case and bear case
Bull case and bear case for PharmaCyte Biotech
Where the evidence on PharmaCyte Biotech disagrees: Mixed on the latest evidence (Oct 17, 2026). Of its 5 thesis points, 1 strengthening, 1 holding and 3 weakening.
Bull case: what the evidence supports
Cash runway is the survival mechanism: PharmaCyte can preserve the Cell-in-a-Box option only if cash remains sufficient to fund development without desperate financing.
Investors should treat reported earnings swings as non-core unless tied to product validation, because PharmaCyte’s value driver is balance-sheet-funded development rather than recurring income.
Bear case: what the evidence questions
Cell-in-a-Box must move from proprietary technology to externally validated cancer-therapy asset, because PharmaCyte has no observable commercial demand engine today.
Operating spending must stay staged to credible milestones, because a pre-revenue biotech cannot create per-share value by increasing burn faster than evidence quality improves.
Liability growth must not crowd out development capital, because the investment case depends on cash reaching Cell-in-a-Box milestones rather than satisfying claims on the balance sheet.
Thesis-Break Engine
What has broken in PharmaCyte Biotech’s thesis
Each break OptimistFi flagged on PharmaCyte Biotech, dated — with what has historically followed the same kind of break across the market, not a forecast for PharmaCyte Biotech.
- Auditor changecondition set before this filing
Across all companies, this kind of break has happened 3,043 times before. Those stocks trailed comparable companies by a median of 6% over the next six months, and 46% of them trailed it by 10 points or more.
MARKET + FINANCIAL SNAPSHOT
The numbers behind the thesis
What Changed
- MixedChanged certifying accountant.
PharmaCyte Biotech filed an SEC 8-K on 2026-10-16: Changed certifying accountant. It is a dated development that tests the current thesis.
- MixedDirector or principal officer change.
PharmaCyte Biotech filed an SEC 8-K on 2026-04-02: Director or principal officer change. It is a dated development that tests the current thesis.
Risks / falsifiers
What could break the thesis
- Regulators refuse to allow meaningful clinical advancement of Cell-in-a-Box or require studies the company cannot fund.
- A required clinical or manufacturing program sharply increases spending before any partner funding is secured.
- Management commits to materially larger development, manufacturing, or corporate spending without a clearly disclosed clinical, regulatory, or strategic milestone.
- Future reported income is generated by a recurring license, royalty, product sale, or partner payment tied to Cell-in-a-Box.
- New debt, preferred securities, litigation obligations, or vendor liabilities take priority over common shareholders before clinical validation.
PMCB news
Loading headlines…
Financial statements
PMCB income statement
Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.
PMCB: quick answers
- What is PMCB's short interest?
- As of October 30, 2026, 50,675 PMCB shares were sold short, 0.47% of its shares outstanding, down 27.7% from the count before. At the stock's average daily volume that is 1.2 days to cover. FINRA publishes the count twice a month. PMCB short interest history

